Hepatocyte growth factor (HGF) is a plasminogen-like protein thought to be a humoral mediator of liver regeneration A 145-kilodalton tyrosyl phosphoprotein observed in rapid response to HGF treatment of intact target cells was identified by immunoblot analysis as the beta subunit of the c-met proto-oncogene product, a membrane-spanning tyrosine kinase Covalent cross-linking of 125I-labeled ligand to cellular proteins of appropriate size that were recognized by antibodies to c-met directly established the c-met product as the cell-surface receptor for HGF

https://science.sciencemag.org/content/sci/251/4995/802.full.pdf

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Hepatocyte growth factor (HGF) is the most potent mitogen for mature parenchymal hepatocytes in primary culture, and seems to be a hepatotrophic factor that acts as a trigger for liver regeneration after partial hepatectomy and liver injury. The partial purification and characterization of HGF have been reported. We have demonstrated that pure HGF from rat platelets is a new growth factor effective at concentrations as low as 1 ng ml-1. The effects of HGF and epidermal growth factor (EGF) are additive. The activity of HGF is not species-specific, although it does not stimulate growth in Swiss 3T3 fibroblasts. HGF has a relative molecular mass (Mr) of 82,000 and is a heterodimer composed of a large alpha-subunit of Mr 69,000 and a small beta-subunit of Mr 34,000. Here we report the amino-acid sequence of human HGF determined by complementary DNA cloning and the expression of biologically active human HGF from COS-1 cells transfected with cloned cDNA. The nucleotide sequence of the human HGF cDNA reveals that both alpha- and beta-chains are contained in a single open reading frame coding for a pre-pro precursor protein of 728 amino acids.

Molecular cloning and expression of human hepatocyte growth factor

Hepatocyte Growth Factor (HGF, also known as Scatter Factor) is a powerful mitogen or motility factor in different cells, acting through the tyrosine kinase receptor encoded by the MET protooncogene Endothelial cells express the MET gene and expose at the cell surface the mature protein (p190MET) made of a 50 kD (alpha) subunit disulfide linked to a 145-kD (beta) subunit HGF binding to endothelial cells identifies two sites with different affinities The higher affinity binding site (Kd = 035 nM) corresponds to the p190MET receptor Sub-nanomolar concentrations of HGF, but not of a recombinant inactive precursor, stimulate the receptor kinase activity, cell proliferation and motility HGF induces repairs of a wound in endothelial cell monolayer HGF stimulates the scatter of endothelial cells grown on three-dimensional collagen gels, inducing an elongated phenotype In the rabbit cornea, highly purified HGF promotes neovascularization at sub-nanomolar concentrations HGF lacks activities related to hemostasis-thrombosis, inflammation and endothelial cells accessory functions These data show that HGF is an in vivo potent angiogenic factor and in vitro induces endothelial cells to proliferate and migrate

https://rupress.org/jcb/article-pdf/119/3/629/1063657/629.pdf

Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor

Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of cancer. Genetic and biochemical data have demonstrated that the growth and motility factor hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the tyrosine kinase MET, have a causal role in all of these processes, thus providing a strong rationale for targeting these molecules in cancer. Parallel progress in understanding the structure and function of HGF/SF, MET and associated signalling components has led to the successful development of blocking antibodies and a large number of small-molecule MET kinase inhibitors. In this Review, we discuss these advances, as well as results from recent clinical studies that demonstrate that inhibiting MET signalling in several types of solid human tumours has major therapeutic value.

/pdf/targeting-met-in-cancer-rationale-and-progress-36bsoy3dx8.pdf

Targeting MET in cancer: rationale and progress

Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats.

https://febs.onlinelibrary.wiley.com/doi/pdf/10.1016/0014-5793%2887%2980475-1

Purification and subunit structure of hepatocyte growth factor from rat platelets

Multihormonal regulation of transcription of the tryptophan 2,3-dioxygenase gene in primary cultures of adult rat hepatocytes with special reference to the presence of a transcriptional protein mediating the action of glucocorticoids.

Katsuhiko Nawa

Papers

Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats.

Purification and subunit structure of hepatocyte growth factor from rat platelets

Multihormonal regulation of transcription of the tryptophan 2,3-dioxygenase gene in primary cultures of adult rat hepatocytes with special reference to the presence of a transcriptional protein mediating the action of glucocorticoids.

Glucocorticoid-dependent expression of the albumin gene in adult rat hepatocytes.

Presence and function of chondroitin-4-sulfate on recombinant human soluble thrombomodulin